192323-08-3

Upstream product

• 172348-63-9 tert-butyl (((1r,4r)-4-(hydroxymethyl)cyclohexyl)methyl)carbamate 
• 1197-18-8 trans-4-aminomethyl-cyclohexyl-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 178972-34-4 toluene-4-sulfonic acid 4-(tert-butoxycarbonylamino-methyl)-cyclohexylmethyl ester 
• 27687-14-5 trans 4-(tert-butyloxycarbonylamino)methylcyclohexanecarboxylic acid 

Downstream Products

• 749866-16-8 4-amino-2-[trans-(4-aminomethylcyclohexyl)methyamino]quinazoline 
• 509142-38-5 {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-carbamic acid tert-butyl ester 
• 192323-09-4 {4-[(4-amino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-carbamic acid tert-butyl ester 
• 853799-80-1 [4-(quinazolin-2-ylaminomethyl)-cyclohexylmethyl]-carbamic acid tert-butyl ester 
• 166168-16-7 trans-((4-aminomethyl)cyclohexylmethyl)carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Discovery of 4-(dimethylamino)quinazolines as potent and selective antagonists for the melanin-concentrating hormone receptor 1

A series of 4-(dimethylamino)quinazoline based antagonists of the melanin-concentrating hormone receptor 1 (MCH-R1) is described. This series was derived from a lead compound, AR129330, identified by HTS of a GPCR-directed library using a functional assay with a constitutively activated (CART) form of the receptor. The preliminary optimization resulted in the identification of compounds 20, 21, and 23.

Compositions and methods for treating mast-cell mediated conditions

Novel compounds, compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders are described. The compounds, compositions and methods are effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, as well as other types of immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis and inflammatory bowel disease, various dermatological conditions, as well as certain viral conditions. The compounds comprise potent and selective inhibitors of the mast cell protease tryptase. The compositions for treating these conditions include oral, inhalant, topical and parenteral preparations as well as devices comprising such preparations.